Leflunomid Sandoz (Leflunomide)

Leflunomide blocks the enzyme dihydroorotate dehydrogenase, which is essential for de novo pyrimidine synthesis. By inhibiting this pathway, the drug limits the proliferation of activated lymphocytes and reduces the production of inflammatory cytokines, thereby dampening the immune response that drives joint damage.

The dosage of Leflunomid Sandoz is individualized and determined by the prescribing physician based on the patient’s clinical condition, laboratory values, and response to therapy. The prescriber will establish the appropriate starting dose and any necessary adjustments during treatment.

Leflunomid Sandoz is contraindicated in pregnancy (Category X) because it can cause fetal malformations. Women of child‑bearing potential must use effective contraception. The drug is also not recommended during breastfeeding, as it may be excreted in milk and affect the infant.

To order Leflunomid Sandoz, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any required import documentation.

The primary alternative to leflunomide is methotrexate, another DMARD. Both reduce disease activity, but leflunomide is taken orally once daily and may be preferred when weekly dosing of methotrexate is problematic. Leflunomide has a different safety profile, with higher risk of liver enzyme elevation and teratogenicity, while methotrexate is associated with mucosal ulcers and pulmonary toxicity.

Leflunomid Sandoz should be stored at ambient temperature below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability throughout its shelf life.

Leflunomid Sandoz is administered orally. The tablet should be swallowed whole with a glass of water, preferably with food to reduce gastrointestinal discomfort. Patients should follow the dosing schedule prescribed by their healthcare professional and not alter the regimen without medical advice.

The most serious risks include severe liver injury, life‑threatening skin reactions such as Stevens‑Johnson syndrome, bone‑marrow suppression leading to anemia or low white‑blood‑cell counts, serious infections, and teratogenic effects if pregnancy occurs. Patients should report any signs of jaundice, rash, fever, or unusual bleeding to their physician promptly.

Leflunomid Sandoz should not be used by pregnant women, individuals with severe hepatic impairment, patients with uncontrolled hypertension, those with active serious infections, or anyone with known hypersensitivity to leflunomide or any of its excipients. A thorough medical evaluation is required before initiating therapy.